A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1

NCT00790673 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis C

Interventions

DRUG: CF 102
DRUG: Placebo

Sponsor

Can-Fite BioPharma